Stayble Therapeutics AB Logo

Stayble Therapeutics AB

Develops treatments for chronic pain originating from spinal disc conditions.

STABL | ST

Overview

Corporate Details

ISIN(s):
SE0013513652 (+1 more)
LEI:
549300WD23DE1US21868
Country:
Sweden
Address:
Lennart Torstenssonsgatan 6, 412 56 Göteborg

Description

Stayble Therapeutics is a clinical-stage pharmaceutical company developing treatments for chronic pain originating from spinal disc conditions. The company's lead drug candidate, STA363, is a minimally invasive, single-injection formulation for intradiscal administration. It is designed to treat chronic low back pain and leg pain (sciatica) caused by disc degeneration and lumbar disc herniation (LDH). STA363 is positioned as a second-line therapy for patients who have not found relief from conservative treatments such as physiotherapy and analgesics, offering an alternative to surgery. The treatment aims to provide long-term pain relief by transforming the disc's nucleus pulposus into connective tissue, thereby stabilizing the disc and reducing pain-causing leakage. The company is advancing STA363 through clinical development to validate its safety and efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stayble Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stayble Therapeutics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stayble Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.